BioSante’s LibiGel Safety Study Concludes As Additional Efficacy Trials Loom On Horizon
This article was originally published in The Pink Sheet Daily
Executive Summary
Ending the cardiovascular and breast cancer safety study provides significant cost savings and there is sufficient data to show safety prior to approval, CEO Simes says.